APA (7th ed.) Citation

Arlegui, H., Bollaerts, K., Bauchau, V., Nachbaur, G., Bégaud, B., & Praet, N. (2020). Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC). Drug Safety, 43(11), 1105. https://doi.org/10.1007/s40264-020-00982-9

Chicago Style (17th ed.) Citation

Arlegui, Hugo, Kaatje Bollaerts, Vincent Bauchau, Gaëlle Nachbaur, Bernard Bégaud, and Nicolas Praet. "Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC)." Drug Safety 43, no. 11 (2020): 1105. https://doi.org/10.1007/s40264-020-00982-9.

MLA (9th ed.) Citation

Arlegui, Hugo, et al. "Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC)." Drug Safety, vol. 43, no. 11, 2020, p. 1105, https://doi.org/10.1007/s40264-020-00982-9.